featured
Capecitabine vs Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After First-Line Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial
J. Clin. Oncol 2021 Sep 13;[EPub Ahead of Print], RA Adams, DJ Fisher, J Graham, JF Seligmann, M Seymour, R Kaplan, E Yates, M Parmar, SD Richman, P Quirke, R Butler, E Brown, F Collinson, S Falk, H Wasan, KK Shiu, G Middleton, L Samuel, RH Wilson, LC Brown, TS MaughanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.